BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

974 related articles for article (PubMed ID: 28719467)

  • 1. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
    Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
    Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pan-tumor screening for NTRK gene fusions using pan-TRK immunohistochemistry and RNA NGS fusion panel testing.
    Koehne de González A; Mansukhani MM; Fernandes H; Hsiao SJ
    Cancer Genet; 2022 Apr; 262-263():47-52. PubMed ID: 35007853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
    Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR
    Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors.
    Csanyi-Bastien M; Lanic MD; Beaussire L; Ferric S; François A; Meseure D; Jardin F; Wassef M; Ruminy P; Laé M
    Am J Surg Pathol; 2021 Nov; 45(11):1487-1498. PubMed ID: 33899788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population.
    Zhao R; Yao F; Xiang C; Zhao J; Shang Z; Guo L; Ding W; Ma S; Yu A; Shao J; Zhu L; Han Y
    J Pathol Clin Res; 2021 Jul; 7(4):375-384. PubMed ID: 33768710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of NTRK fusions in glioblastoma: fluorescent in situ hybridisation is more useful than pan-TRK immunohistochemistry as a screening tool prior to RNA sequencing.
    Bourhis A; Caumont C; Quintin-Roué I; Magro E; Dissaux G; Remoué A; Le Noac'h P; Douet-Guilbert N; Seizeur R; Tyulyandina A; Schick U; Merlio JP; Marcorelles P; Cappellen D; Uguen A
    Pathology; 2022 Feb; 54(1):55-62. PubMed ID: 34518039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing.
    Lee YC; Chen JY; Huang CJ; Chen HS; Yang AH; Hang JF
    Endocr Pathol; 2020 Dec; 31(4):348-358. PubMed ID: 32880785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer.
    Conde E; Hernandez S; Sanchez E; Regojo RM; Camacho C; Alonso M; Martinez R; Lopez-Rios F
    Arch Pathol Lab Med; 2021 Aug; 145(8):1031-1040. PubMed ID: 33112951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant.
    Wu S; Liu Y; Shi X; Zhou W; Zeng X
    Dig Liver Dis; 2023 Dec; 55(12):1757-1764. PubMed ID: 37142453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
    Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
    Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Diagnostic Value of Pan-Trk Expression to Detect Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion in CNS Tumours: A Study Using Next-Generation Sequencing Platform.
    Mohamed F; Kurdi M; Baeesa S; Sabbagh AJ; Hakamy S; Maghrabi Y; Alshedokhi M; Dallol A; Halawa TF; Najjar AA; Fdl-Elmula I
    Pathol Oncol Res; 2022; 28():1610233. PubMed ID: 35295612
    [No Abstract]   [Full Text] [Related]  

  • 13. NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC.
    Kong Y; Bu R; Parvathareddy SK; Siraj AK; Siraj N; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
    Eur J Endocrinol; 2021 Apr; 184(4):503-511. PubMed ID: 33524004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sensitivity of pan-TRK immunohistochemistry in solid tumours: A meta-analysis.
    Hondelink LM; Schrader AMR; Asri Aghmuni G; Solleveld-Westerink N; Cleton-Jansen AM; van Egmond D; Boot A; Ouahoud S; Khalifa MN; Wai Lam S; Morreau H; Bovee JVMG; van Wezel T; Cohen D
    Eur J Cancer; 2022 Sep; 173():229-237. PubMed ID: 35933886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions.
    Brčić I; Godschachner TM; Bergovec M; Igrec J; Till H; Lackner H; Scheipl S; Kashofer K; Brodowicz T; Leithner A; Szkandera J; Liegl-Atzwanger B
    Mod Pathol; 2021 Feb; 34(2):396-407. PubMed ID: 32860002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
    Albert CM; Davis JL; Federman N; Casanova M; Laetsch TW
    J Clin Oncol; 2019 Feb; 37(6):513-524. PubMed ID: 30592640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using pan-TRK and RET Immunohistochemistry for the Detection of Fusion Types of Salivary Gland Secretory Carcinoma.
    Su YJ; Lee YH; Jin YT; Hsieh MS
    Appl Immunohistochem Mol Morphol; 2022 Apr; 30(4):264-272. PubMed ID: 35384876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NTRK fusions and Trk proteins: what are they and how to test for them.
    Weiss LM; Funari VA
    Hum Pathol; 2021 Jun; 112():59-69. PubMed ID: 33794242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas.
    Zhang Z; Pang J; Chen L; Chen J; Li J; Liu H; Wang J; Wu H; Liang Z
    Hum Pathol; 2022 Nov; 129():21-31. PubMed ID: 35977594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes.
    Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L
    Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.